Saturday 17 October 2026
Export CRVS’s income statement to Excel — free account
Corvus Pharmaceuticals, Inc.
CRVS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 90.0% and free cash flow fell 171.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
9.52
0.33
−3.35%
Follow CRVS
Corvus Pharmaceuticals, Inc. (CRVS) P/E ratio
Corvus Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 88.5× (October 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 88.5×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DNA Ginkgo Bioworks Holdings, Inc. compare | n/m |
| KURA Kura Oncology, Inc. compare | n/m |
| VSTM Verastem, Inc. compare | n/m |
| HELP Cybin Inc. compare | n/m |
| GLUE Monte Rosa Therapeutics, Inc. compare | n/m |
| CRVS Corvus Pharmaceuticals, Inc. | n/m |
| ALMS Alumis Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| ARDX Ardelyx, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)